| 臺大學術典藏 |
2022-01-12T07:07:15Z |
Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
|
Tsai C.-H.; Yao C.-Y.; Tien F.-M.; Tang J.-L.; Kuo Y.-Y.; Chiu Y.-C.; Lin C.-C.; Tseng M.-H.; Peng Y.-L.; Liu M.-C.; Liu C.-W.; Yao M.; Lin L.-I.; Chou W.-C.; Chen C.-Y.; HSIN-AN HOU; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:14Z |
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
|
Huang H.-H.; Chen F.-Y.; Chou W.-C.; HSIN-AN HOU; Ko B.-S.; Lin C.-T.; Tang J.-L.; Li C.-C.; Yao M.; Tsay W.; Hsu S.-C.; Wu S.-J.; Chen C.-Y.; Huang S.-Y.; Tseng M.-H.; Tien H.-F.; Chen R.-H. |
| 臺大學術典藏 |
2022-01-12T07:07:14Z |
Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study
|
Liu J.-H.; Liao X.-W.; Chen C.-H.; Yao M.; Li C.-C.; Lin C.-T.; Tsai C.-H.; Chou W.-C.; HSIN-AN HOU; Huang S.-Y.; Wu S.-J.; Chen Y.-C.; Tien H.-F.; Tang J.-L.; Ko B.-S. |
| 臺大學術典藏 |
2022-01-12T07:07:12Z |
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
|
Wang Y.-W.; Tsai C.-H.; Lin C.-C.; Tien F.-M.; Chen Y.-W.; Lin H.-Y.; Yao M.; Lin Y.-C.; Lin C.-T.; Cheng C.-L.; Tang J.-L.; Chou W.-C.; HSIN-AN HOU; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:11Z |
ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
|
Wang Y.-H.; Lin C.-C.; Lee S.-H.; Tsai C.-H.; Wu S.-J.; HSIN-AN HOU; Huang T.-C.; Kuo Y.-Y.; Yao M.; Chang K.; Lin C.-W.; Lin Y.-C.; Tien F.-M.; Chou W.-C.; Tang J.-L.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:10Z |
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
|
Tien F.-M.; Tsai C.-H.; Huang S.-C.; Liu J.-H.; Chen C.-Y.; Kuo Y.-Y.; Chuang Y.-K.; Tseng M.-H.; Peng Y.-L.; Liu M.-C.; Liu C.-W.; Liao X.-W.; Lin L.-I.; Wu Y.-S.; Hou M.-F.; Wu S.-J.; Hsu S.-C.; Ko B.-S.; Chou W.-C.; Yao M.; HSIN-AN HOU; Tang J.-L.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:09Z |
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; HSIN-AN HOU; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; Kuo S.-H.; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-01-12T07:07:07Z |
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
|
Tsai C.-H.; Tang J.-L.; Tien F.-M.; Kuo Y.-Y.; Wu D.-C.; Lin C.-C.; Tseng M.-H.; Peng Y.-L.; Hou M.-F.; Chuang Y.-K.; Liu M.-C.; Liu C.-W.; Yao M.; Lin L.-I.; Chou W.-C.; Chen C.-Y.; HSIN-AN HOU; Tien H.-F. |
| 國家衛生研究院 |
2022 |
Distinct immunogenetic profiles of chronic lymphocytic leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study
|
Yao, CY;Agathangelidis, A;Chuang, SS;Tsou, HH;Feng, WL;Liu, TC;Chen, TY;Yu, YB;Yeh, SP;Yao, M;Wang, CC;Lin, J;Hwang, WL;Gau, JP;Chou, WC;Chao, TY;Lin, LI;Tien, HF;Ghia, P;Wu, SJ |
| 國立成功大學 |
2022 |
Incidence and predictors of idiopathic pneumonia syndrome in hematopoietic stem cell transplant patients: a nationwide registry study
|
Liu, M.A.;Lee, C.-C.;Phung, Q.;Dao, Q.-L.;Tehrani, B.;Yao, M.;Li, C.-C.;Wu, K.-H.;Chen, T.-C.;Gau, J.-P.;Li, S.-S.;Wang, P.-N.;Liu, Y.-C.;Wang, T.-F.;Chiou, L.-W.;Lee, M.-Y.;Yu, M.-S.;Wang, C.-C.;Lin, S.-C.;Chen, Y.-C.;Chao, T.-Y.;Ma, Ma M.-C.;Chen, Chen C.-C.;Chang, H.-H. |
